Drugs / Pegmolesatide
Pegmolesatide
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT02366325 | Jul 2014 → Dec 2015 | anemia, chronic renal failure syndrome | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT02403362 | Jun 2014 → Oct 2015 | anemia, chronic renal failure syndrome | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT07045155 | Aug 2025 → Dec 2027 expected | anemia due to chronic disorder, end stage renal failure | Chinese PLA General Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06946394 | May 2025 → Jun 2026 overdue | aregenerative anemia | The First Affiliated Hospital of Dalian Medical University | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07136792 | Sep 2025 → Dec 2026 expected | anemia due to chronic disorder | Guangdong Provincial People's Hospital | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pegmolesatide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07136792 ↗ |
| Known as | EPO-018B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02366325 ↗ |
| Known as | Pegol-Sihematide | “A Phase 2, Open-Label, Multi-Center , Dose-Ranging Study of the Safety and Efficacy of Pegol-Sihematide (EPO-018B) for the Treatment of Anemia in Patients With Chronic Kidney...” NCT02403362 ↗ |
| Action | Activate | “Pegmolesatide, a synthetic peptide-based erythropoietin (EPO) receptor agonist” PMID 37954906 ↗ Oct 2023 |
| Modality | Peptide | “Pegmolesatide, a synthetic peptide-based erythropoietin (EPO) receptor agonist” PMID 37954906 ↗ Oct 2023 |
| Route | Intravenous | “multiple intravenous doses of EPO-018B” NCT02366325 ↗ |